Last reviewed · How we verify
saline.9%
9% saline solution restores electrolyte balance and osmotic pressure by delivering a hypertonic sodium chloride solution to the bloodstream.
9% saline solution restores electrolyte balance and osmotic pressure by delivering a hypertonic sodium chloride solution to the bloodstream. Used for Severe symptomatic hyponatremia, Cerebral edema, Hypovolemic shock.
At a glance
| Generic name | saline.9% |
|---|---|
| Sponsor | Hvidovre University Hospital |
| Drug class | Electrolyte replacement / Hypertonic saline |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Emergency Medicine |
| Phase | FDA-approved |
Mechanism of action
9% saline is a hypertonic solution containing 9 grams of sodium chloride per 100 mL of water. When administered intravenously, it increases serum osmolality and draws fluid from intracellular and interstitial spaces into the vascular compartment, expanding intravascular volume and restoring electrolyte homeostasis. This mechanism is used to treat severe hyponatremia, cerebral edema, and hypovolemic shock.
Approved indications
- Severe symptomatic hyponatremia
- Cerebral edema
- Hypovolemic shock
- Increased intracranial pressure
Common side effects
- Hypernatremia
- Phlebitis at infusion site
- Hyperchloremia
- Fluid overload
Key clinical trials
- Endorotor Resection In Refractory Barrett's Dysplasia Patients (NA)
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (PHASE2)
- Volume Reduction for Open Fracture Irrigation (PHASE4)
- The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease (PHASE4)
- Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC (PHASE2)
- Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |